27th March 2023 Content supplied by: Sino Biological US Inc.
Recombinant Antigens for 2023-2024 Influenza Vaccine Strains
On February 24th, 2023, the World Health Organization (WHO) announced the recommendations for influenza vaccine composition for the 2023-2024 northern hemisphere influenza season. To support vaccine research, Sino Biological has released the recombinant antigens for 2023-2024 influenza vaccine strains.
With the world’s largest viral antigen collection, ProVir®, Sino Biological provides a range of recombinant influenza antigen products, including Hemagglutinin (HA), Neuraminidase (NA), and Nucleoprotein (NP) proteins from all WHO-recommended vaccine strains in recent years. An extensive collection of monoclonal antibodies against the flu antigens are also available to support the development of relevant assays and diagnostic kits.
Visit Sino Biological or click on the Request Information button below.
Date Published: 27th March 2023
Source article link: View
Sino Biological Announces Construction of
Influenza Vaccine Development and Production